Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: HUMALOG

Summary for Tradename: HUMALOG

Suppliers: see list3
2013 Sales:$1,184,189,000
patent expirations by year for

Pharmacology for Tradename: HUMALOG

Drug ClassInsulin Analog

Clinical Trials for: HUMALOG

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
Status: Completed Condition: Diabetes Mellitus, Type 2

Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics
Status: Withdrawn Condition: Type I Diabetes

A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
Status: Recruiting Condition: Diabetes Mellitus Type 1

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Status: Completed Condition: Diabetes Mellitus, Type 1

Phase II PK Study With Humalog and Humulin R With and Without rHuPH20 in T1DM
Status: Completed Condition: Type 1 Diabetes Mellitus

Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)
Status: Completed Condition: Diabetes Mellitus, Type 2

A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants
Status: Completed Condition: Healthy Participants

Bioequivalence of Two Lispro Formulations
Status: Completed Condition: Healthy Volunteers

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
Status: Completed Condition: Diabetes Mellitus, Type 2

Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
Status: Completed Condition: Gestational Diabetes Mellitus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
insulin lispro recombinant
INJECTABLE;INJECTION020563Jun 14, 1996RXYes<disabled><disabled>
insulin lispro recombinant
INJECTABLE;INJECTION020563Jun 14, 1996RXYes5,474,978<disabled>YY<disabled>
insulin lispro recombinant
INJECTABLE;INJECTION020563Sep 6, 2007RXYes5,474,978<disabled>YY<disabled>
insulin lispro recombinant
INJECTABLE;INJECTION020563Sep 6, 2007RXYes7,291,132<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology